Menu
Not yet recruiting NCT07429162

Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection

Phase I Interventional Mycobacterium Abscessus Infection Bacteriophage Therapy Pulmonary Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: DP-QB-MYA-002.
Who it may be relevant to
Registry conditions: Mycobacterium Abscessus Infection, Bacteriophage Therapy, Pulmonary Disease. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

DP-QB-MYA-002 Phage Cocktail for Chronic Multidrug-Resistant (MDR) Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection

Overview

The objective of this study is to evaluate mycobacteriophage therapy using in-vitro validated mycobacteriophage DP-QB-MYA-002 in combination with conventional antimycobacterial agents for the treatment of multidrug-resistant Mycobacterium abscessus pulmonary disease, with the goal of reducing mycobacterial burden and improving pulmonary outcomes.

Interventions

  • Biological DP-QB-MYA-002
    In-vitro effective Mycobacteriophage DP-QB-MYA-002 against specific strain of Mycobacterium abscessus ssp abscessuss

Primary outcome measures

  • Time to Sputum Culture Conversion (Microbiologic Response) [Time frame: 1 year]
Secondary outcome measures (5)
  • Change in Volume of Sputum Production (Clinical Response) [Time frame: 1 year]
  • Change in frequency of Cough (Clinical Response) [Time frame: 1 year]
  • Change in FEV1 (Clinical Response) [Time frame: 1 year]
  • Change in BMI (Clinical Response) [Time frame: 1 year]
  • Radiographic Response [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • Consent to participation

Exclusion criteria

  • non-consent to participation

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07429162 · PHAGE-2026-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗